|Day Low/High||5.99 / 6.30|
|52 Wk Low/High||5.61 / 18.60|
Goldberg Law PC announces that it is investigating TG Therapeutics, Inc.
Levi & Korsinsky, LLP announces that it has commenced an investigation of TG Therapeutics, Inc.
TG Therapeutics (TGTX) filed to adjust protocol for its GENUINE clinical study of a drug combination for leukemia.
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
Investor Conference Call to be held tomorrow, Thursday, October 13, 2016 at 8:30am ET
Investors eyeing a purchase of TG Therapeutics Inc stock, but tentative about paying the going market price of $7.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $7.50 strike, which has a bid at the time of this writing of $1.40.
Presentation Scheduled for Tuesday September 27, 2016 at 11:30am ET
These 2 small-caps have strong pipelines and are becoming analyst darlings.
Small biotech tanked on weak earnings, but still seems promising.
Investor Conference Call to be Held Today, Monday, August 8, 2016 at 8:30am ET
Investor Conference Call to be held Monday, August 8, 2016 at 8:30am ET
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in TG Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Combination of TGR-1202 + Ibrutinib appears well-tolerated and active in relapsed/refractory CLL patients treated with the combination
Presentation Scheduled for Friday June 10, 2016 at 10:00am ET
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a weak on high relative volume candidate
Updates on smaller housing, retail and biotech plays recently mentioned on these pages.
Investor Reception to be Held on Monday June 6, 2016 at 7:00pm CT at the Peninsula Chicago Hotel with Presentations by Leading Clinical Investigators
Presentations demonstrate the safety and efficacy of TGR-1202 in combination with ublituximab as well as in combination with ibrutinib in patients with CLL and NHL